Stent

Medtronic announced that a stent graft system for the minimally invasive repair of thoracoabdominal aortic aneurysms has received breakthrough device designation from the FDA.

SAN FRANCISCO — An intravascular lithotripsy device used for vessel preparation for stenting in patients with severely calcified coronary lesions was safe and effective, according to results from the DISRUPT CAD II study presented at TCT 2019.

SAN FRANCISCO — Magnesium-based bioresorbable scaffolds resulted in a greater capacity of vasomotor response to pharmacological agents compared with sirolimus-eluting stents among patients with STEMI, according to 1-year follow-up data from the MAGSTEMI trial presented at TCT 2019.

SAN FRANCISCO — The rate of adverse events at 5 years increased among patients assigned a bioresorbable vascular scaffold compared with those assigned an everolimus-eluting coronary stent system, according to new data from the ABSORB III trial presented at the Transcatheter Cardiovascular Therapeutics Scientific Symposium.

Implantation of a trabecular micro-bypass stent in patients with all types of glaucoma and moderate to severe glaucoma damage showed long-term efficacy and safety in a real-world, prospective, nonrandomized study at the University of Heidelberg, Germany.

PARIS — In this video exclusive, Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital, professor of medicine at Harvard Medical School and Cardiology Today Editorial Board Member, provides a deep dive on the THEMIS and THEMIS-PCI trials presented at the European Society of Cardiology Congress.

Orchestra BioMed Inc., in partnership with Terumo Corporation, announced its sirolimus-eluting balloon for the treatment of below-the-knee peripheral artery disease, has received breakthrough device designation from the FDA.

In a retrospective analysis of Japanese patients with peripheral artery disease treated with paclitaxel-coated devices or other devices, paclitaxel-coated devices were not associated with elevated mortality risk at 5 years.

Shockwave Medical announced that the FDA has granted a breakthrough device designation to its intravascular lithotripsy device for the treatment of complex calcified CVD.

Comparison of a drug-eluting stent with a bare-metal stent in patients with CAD who were at high risk for bleeding.